What are the key immune mechanisms underlying transplant tolerance, and which novel strategies show promise for clinically safe rejection prevention?

Question

Despite the continuous progress of immunosuppressants, long-term transplant rejection and drug toxicity remain major challenges. Transplant tolerance (a donor specific immune non responsive state that does not rely on sustained immune suppression) remains a difficult goal to achieve. The key mechanisms include central and peripheral immune regulation (such as regulatory T cells, immune exhaustion, clonal clearance, myeloid suppressor cells, etc.). The new strategies include co stimulatory signal blockade, regulatory cell therapy, chimeric induction, and tolerance promoting biomaterials. Please ask experts to clarify which mechanisms and pathways have the greatest clinical translational potential, and which combination therapies can safely achieve long-lasting tolerance in humans.

Emmanuel Sunday Okeke · Answer

I think that the mechanisms with the most potential for translation are the ones that have already been tested in the clinic, like regulatory T cell (Treg)-mediated suppression and co-stimulatory pathway blockade. Tregs are particularly intriguing as they offer antigen-specific regulation rather than generalized immunosuppression, and preliminary clinical studies indicate their safe administration. The difficulty, however, is keeping them stable and working well over time in an environment that causes inflammation. Blocking co-stimulation (for example, by targeting the CD28–CD80/86 or CD40 pathways) is also very important because it directly stops T cell activation. It is possible to lower toxicity compared to calcineurin inhibitors with drugs like belatacept, but these drugs alone do not reliably cause true tolerance. 
 
 Mixed chimerism is one of the few methods that has come close to achieving operational tolerance in humans. This is probably because it uses central tolerance mechanisms like clonal deletion. That said, the conditioning regimens and the risk of complications like GVHD still make it hard to use this on a wide scale. 
 
I believe it is becoming more and more clear that one strategy alone is probably not enough. The most promising direction seems to be combination approaches, especially combining co-stimulation blockade with Treg-based therapies or transient chimerism with short-term immunosuppression. There is also more and more interest in using biomaterials or nanoparticle-based systems to deliver donor antigens in a way that doesn't cause an immune response, but these are still in the early stages. The field seems to be moving away from total suppression and toward targeted, multi-modal immune regulation. The goal is to achieve donor-specific tolerance while keeping protective immunity.

Yared Abate · Answer

Stopping rejection is moving towards using cells or nanoparticles that can help the body not reject the donor cells instead of using strong medicines that can hurt the whole body. The best ways to do this that are being used in clinics are giving the special cells called Tregs that are just, for the donor and using a medicine called belatacept that helps stop the recipient cells from getting too excited. There is also another way that's very powerful but also has more risks, which is called mixed chimerism and it helps the body get used to the donor cells. Probably we will need to use a combination of these things like giving an amount of a medicine called IL-2 and another medicine that stops the recipient cells from getting too excited and also giving the patient Tregs to make sure the body does not reject the donor cells and to keep the patient safe.

What are the key immune mechanisms underlying transplant tolerance, and which novel strategies show promise for clinically safe rejection prevention?

Post an Answer

Yared Abate

What is the best way to deplete resident macrophages in the heart?

Why do cancer treatment options (chemotherapies + radiations) have outcome failure rates of 90% (+/-5) for solid tumors?

What is the relationship between free radicals and the inflammation process during Chronic diseases?

Any herbal medicines used for hepatitis, possible mechanism of action, and if possible attached pictures of plants with citations

How long does it take for a glycoprotein to be synthesised de novo, processed in the ER/Golgi apparatus and transported to the cell membrane?

Type

Status

Bounty

Created

Answer Count

Vote Count

Creator

Tags

Share Page

Copy URL to Clipboard

What are the key immune mechanisms underlying transplant tolerance, and which novel strategies show promise for clinically safe rejection prevention?

Post an Answer

Yared Abate

What is the best way to deplete resident macrophages in the heart?

Why do cancer treatment options (chemotherapies + radiations) have outcome failure rates of 90% (+/-5) for solid tumors?

What is the relationship between free radicals and the inflammation process during Chronic diseases?

Any herbal medicines used for hepatitis, possible mechanism of action, and if possible attached pictures of plants with citations

How long does it take for a glycoprotein to be synthesised de novo, processed in the ER/Golgi apparatus and transported to the cell membrane?

Type

Status

Bounty

Created

Answer Count

Vote Count

Creator

Tags